gabapentin has been researched along with Aging in 9 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 2 |
| Yan, K | 1 |
| Li, C | 2 |
| Li, Y | 4 |
| Li, L | 3 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 5 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Wang, Y | 4 |
| Hu, X | 1 |
| Li, Z | 2 |
| Shen, Y | 1 |
| Hu, D | 1 |
| Chen, H | 1 |
| Wu, X | 1 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Zhang, X | 2 |
| Yang, X | 2 |
| Zhang, J | 2 |
| Wang, H | 1 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Wang, J | 2 |
| Geng, Y | 1 |
| Zhang, Y | 3 |
| Wang, X | 2 |
| Liu, J | 2 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Li, S | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 1 |
| Zhao, W | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Chen, X | 2 |
| Mo, J | 1 |
| Zhang, S | 2 |
| Li, X | 1 |
| Huang, T | 1 |
| Zhu, Q | 1 |
| Wang, S | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 1 |
| Frew, R | 1 |
| Guo, X | 1 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 1 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 1 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 1 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Wang, B | 1 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 1 |
| Xu, C | 1 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Shah, D | 1 |
| Agrawal, S | 1 |
| Galkin, VV | 2 |
| Nesterova, MV | 2 |
| Emel'ianov, VV | 1 |
| Joffe, H | 1 |
| Soares, CN | 1 |
| Cohen, LS | 1 |
| Armijo, JA | 1 |
| Pena, MA | 1 |
| Adín, J | 1 |
| Vega-Gil, N | 1 |
| Rowan, AJ | 1 |
| Ramsay, RE | 1 |
| Collins, JF | 1 |
| Pryor, F | 1 |
| Boardman, KD | 1 |
| Uthman, BM | 1 |
| Spitz, M | 1 |
| Frederick, T | 1 |
| Towne, A | 1 |
| Carter, GS | 1 |
| Marks, W | 1 |
| Felicetta, J | 1 |
| Tomyanovich, ML | 1 |
| Yoshino, A | 1 |
| Nelson, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| The Efficacy of ACupuncture On Menopausal Symptoms (ACOM): A Randomized Controlled Trial[NCT02746497] | 70 participants (Actual) | Interventional | 2016-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00438451)
Timeframe: 58 weeks
| Intervention | proportion of participants (Mean) |
|---|---|
| Levetiracetam | 0.61 |
| Carbamazepine | 0.46 |
| Lamotrigine | 0.56 |
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 43 |
| Carbamazepine | 33 |
| Lamotrigine | 38 |
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 48 |
| Carbamazepine | 39 |
| Lamotrigine | 49 |
(NCT00438451)
Timeframe: 52 weeks
| Intervention | proportion of seizure-free days (Number) |
|---|---|
| Levetiracetam | 0.99 |
| Carbamazepine | 0.99 |
| Lamotrigine | 0.99 |
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
| Intervention | units on a scale (Mean) |
|---|---|
| Levetiracetam | 26.0 |
| Carbamazepine | 26.0 |
| Lamotrigine | 25.4 |
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
| Intervention | number of seizures (Number) |
|---|---|
| Levetiracetam | 168 |
| Carbamazepine | 131 |
| Lamotrigine | 130 |
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | NA |
| Lamotrigine | NA |
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | 265 |
| Lamotrigine | NA |
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
| Carbamazepine | 27.3 | 11.4 | 38.7 |
| Lamotrigine | 23.7 | 10.8 | 34.5 |
| Levetiracetam | 22.2 | 10.5 | 32.7 |
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
| Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
| Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
| Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Without pathological findings | Borderline | Impaired | |
| Carbamazepine | 34 | 17 | 33 |
| Lamotrigine | 31 | 15 | 39 |
| Levetiracetam | 38 | 10 | 36 |
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Carbamazepine | 16 | 56 | 8 |
| Lamotrigine | 15 | 53 | 13 |
| Levetiracetam | 15 | 61 | 6 |
5 reviews available for gabapentin and Aging
| Article | Year |
|---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Vasomotor symptoms: viewpoint from the Indian subcontinent and management of a common menopausal problem.
Topics: Aging; Amines; Antihypertensive Agents; Asian People; Complementary Therapies; Cyclohexanecarboxylic | 2010 |
Assessment and treatment of hot flushes and menopausal mood disturbance.
Topics: Acetates; Aging; Amines; Anti-Anxiety Agents; Cognition Disorders; Cyclohexanecarboxylic Acids; Fema | 2003 |
[Epilepsy in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Amines; Anticonvulsants; Cerebrovascular Disorders; Comorbidity; Cyc | 2007 |
Menopause.
Topics: Adult; Aging; Amines; Cyclohexanecarboxylic Acids; Estrogen Replacement Therapy; Female; Gabapentin; | 2008 |
2 trials available for gabapentin and Aging
| Article | Year |
|---|---|
[Biological age and the pain syndrome at diabetic polyneuropathy].
Topics: Adult; Aging; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; | 2011 |
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
Topics: Aged; Aging; Amines; Anticonvulsants; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acid | 2005 |
2 other studies available for gabapentin and Aging
| Article | Year |
|---|---|
[Efficacy of convalis in the treatment of pain diabetic polyneuropathy and it's influence on biological age].
Topics: Adult; Age Factors; Aging; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathi | 2012 |
Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Amines; Analysis of Variance; Child; | 2004 |